This result was not influenced by the dose of dipyridamole or type of presenting vascular disease .
For patients who presented with arterial vascular disease , there was no evidence that dipyridamole , in the presence or absence of another antiplatelet drug reduced the risk of vascular death , though it reduces the risk of further vascular events .
This benefit was found only in patients presenting after cerebral ischaemia .
There was no evidence that dipyridamole alone was more efficacious than aspirin
BACKGROUND Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events ( 4 % to 11 % annually ) .
Aspirin reduces that risk by 13 % .
In one trial , adding dipyridamole to aspirin was associated with a 22 % risk reduction compared with aspirin alone .
OBJECTIVES To assess the efficacy and safety of dipyridamole versus control in the secondary prevention of vascular events in patients with vascular disease .
[Treatment of unstable angina with dipyridamole combined with low doses of aspirin. A multicenter pilot double-blind controlled study].
In order to assess the usefulness of a combination of low-dose aspirin ( 25 mg b.i.d . ) with dipyridamole ( 200 mg b.i.d . ) in the prevention of major coronary events in patients with acute unstable angina , we performed a prospect i ve , double-blind , placebo-controlled study involving 88 consecutive patients admitted to three Hospital Departments of Cardiology . The patients entered the study as soon as possible after hospital admission , and were treated and followed up to one year . There was no appreciable difference in side effects and adverse reactions between the treatment and control group . The incidence of cardiac death and /or nonfatal myocardial infa rct ion during the whole period of observation was 14 % ( 6/44 ) in the treatment group and 25 % ( 11/44 ) in the placebo group by " intention-to-treat " analysis ; 16 % ( 4/25 ) and 32 % ( 10/31 ) , respectively , by " drug-efficacy " analysis ( p = 0.21 by Fisher 's exact test , non significant difference ) . However , when considering the only events occurred in the first month ( 2/44 in the treatment group and 9/44 in the placebo group , amounting to 4.5 and 20 percent , respectively ) , the combination of  dipyridamole  with  low-dose aspirin  reached a statistically significant protective effect ( p = 0.04 ) . The results of this pilot study provide strong evidence for a beneficial effect of the regimen tested in patients with acute unstable angina , at least in the first weeks of treatment , while at the same time suggesting a safe alternative for patients with contraindications to higher doses of aspirin
This result was not influenced by the dose of dipyridamole or type of presenting vascular disease .
For patients who presented with arterial vascular disease , there was no evidence that dipyridamole , in the presence or absence of another antiplatelet drug reduced the risk of vascular death , though it reduces the risk of further vascular events .
This benefit was found only in patients presenting after cerebral ischaemia .
There was no evidence that dipyridamole alone was more efficacious than aspirin
BACKGROUND Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events ( 4 % to 11 % annually ) .
Aspirin reduces that risk by 13 % .
In one trial , adding dipyridamole to aspirin was associated with a 22 % risk reduction compared with aspirin alone .
OBJECTIVES To assess the efficacy and safety of dipyridamole versus control in the secondary prevention of vascular events in patients with vascular disease .